+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Savolitinib Tablets Market - Global Forecast 2025-2030- Product Image
Savolitinib Tablets Market - Global Forecast 2025-2030- Product Image
Sale

Savolitinib Tablets Market - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 184 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6129294
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Savolitinib tablets are redefining the landscape of orphan oncology therapeutics, as leading biopharmaceutical innovators leverage molecular targeting to address previously unserved oncology segments. This market signals a transition from conventional therapies to advanced, genetic-profile-driven solutions, accelerating differentiation and market growth.

Market Snapshot: Precision Oncology Drives Savolitinib Tablet Market Growth

The global market for savolitinib tablets is expanding rapidly, propelled by the adoption of precision oncology and the increasing recognition of MET pathway alterations as therapeutic targets. With notable market size and a CAGR projected at [data unavailable] through the forecast period, senior decision-makers are closely tracking evolving regulatory, technological, and supply chain dynamics that inform strategy and competitive positioning. The growing prevalence of non-small cell lung cancer and continued investments in biomarker-driven drug development highlight persistent demand. Collaborations across diagnostics, pharmaceutical manufacturers, and clinical research organizations are further shaping access and innovation trends.

Scope & Segmentation: Unpacking the Savolitinib Tablets Market

This report delivers comprehensive coverage of the savolitinib tablets landscape, integrating multi-dimensional market segmentation. Key breakdowns include:

  • Indication: Encompasses gastric cancer, non-small cell lung cancer (both C-Met exon 14 skipping mutation positive and EGFR mutation positive cohorts), and renal cell carcinoma.
  • Distribution Channels: Includes hospital pharmacies, online pharmacies, and retail pharmacies, each playing specialized roles in patient access and adherence support.
  • Dosage Strengths: Features 100 mg and 200 mg formulations, allowing clinicians to individualize patient regimens.
  • Line of Therapy: Covers first-line, second-line, and third-line (and beyond), with implications for clinical protocol design and reimbursement benchmarks.
  • Patient Types: Segments into adult and pediatric populations, supporting tailored safety, efficacy, and risk-benefit analyses.
  • Regions: Americas: United States (California, Texas, New York, Florida, Illinois, Pennsylvania, Ohio), Canada, Mexico, Brazil, Argentina.
    Europe, Middle East & Africa: United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland.
    Asia-Pacific: China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan.
  • Key Companies: AstraZeneca Pharmaceutical (China) Investment Co., Ltd., and Hutchison China MediTech Limited are among the central innovators advancing savolitinib development and commercialization.

Key Takeaways: Strategic Insights for Decision-Makers

  • Targeted inhibition of the MET pathway with savolitinib represents a major transition in oncology strategies, prioritizing patient populations defined by actionable genetic mutations.
  • Innovations in companion diagnostics, including those for MET exon 14 skipping and EGFR mutations, streamline patient selection and accelerate regulatory timelines.
  • Global market heterogeneity—driven by regional reimbursement models, procurement strategies, and healthcare infrastructure—necessitates flexible, localized commercialization plans.
  • Combination regimens involving savolitinib and EGFR inhibitors offer compelling synergy for mutation-driven non-small cell lung cancer, expanding therapeutic opportunities beyond monotherapy.
  • Emerging pediatric indications and novel oral formulations reflect ongoing investments in differentiated dose, patient safety, and clinical performance.
  • Supply chain optimization and resilient distribution frameworks have become pivotal, especially in the context of new tariff structures and regional manufacturing partnerships.

Tariff Impact: Navigating the 2025 United States Tariff Regime

The introduction of the 2025 United States tariff regime has prompted industry-wide recalibration across pharmaceutical supply chains. Increased duties on active pharmaceutical ingredients necessitate new sourcing strategies, closer supply chain audits, and contingency production plans. Many stakeholders now emphasize local manufacturing and alliances with contract development organizations to mitigate supply disruptions and manage regulatory compliance. As a result, procurement frameworks are being adapted to ensure consistent availability of savolitinib and maintain adherence to best manufacturing practices.

Methodology & Data Sources

This research integrates primary interviews with oncology experts, pharmacoeconomists, regulatory specialists, and supply chain professionals, ensuring multifaceted insights. Comprehensive secondary research from peer-reviewed literature, regulatory documents, and industry disclosures further reinforces data quality. Analytical models were applied to validate clinical, pricing, and distribution findings.

Savolitinib Tablets Market: Why This Report Matters

  • Senior stakeholders gain a data-driven playbook for navigating regulatory, competitive, and manufacturing complexities.
  • Actionable market segmentation supports informed investment and partnership decisions in high-growth submarkets.
  • Timely analysis of evolving tariff regimes, real-world evidence, and regional access dynamics informs forward-looking oncology strategies.

Conclusion

This report equips decision-makers with actionable insights to steer savolitinib strategies through complex regulatory, clinical, and supply chain environments. Stakeholders can drive innovation and maximize market opportunities across the oncology continuum.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Growing adoption of savolitinib tablets in MET exon 14 skipping NSCLC treatment protocols across Asia-Pacific markets
5.2. Strategic collaboration between biotech firms and local distributors to expand savolitinib tablet access in emerging markets
5.3. Surge in real-world evidence publications demonstrating savolitinib tablet efficacy in diverse patient populations
5.4. Regulatory milestones achieved with savolitinib tablet approval for gastric cancer indications in European markets
5.5. Competitive pricing pressures intensify as generic MET inhibitor candidates emerge against savolitinib tablets
5.6. Advancements in companion diagnostics development for patient selection in savolitinib tablet therapy
5.7. Healthcare payer negotiations focus on value-based reimbursement models for savolitinib tablet coverage
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Savolitinib Tablets Market, by Indication
8.1. Introduction
8.2. Gastric Cancer
8.3. Non-Small Cell Lung Cancer
8.3.1. C-Met Exon 14 Skipping Mutation Positive
8.3.2. Egfr Mutation Positive
8.4. Renal Cell Carcinoma
9. Savolitinib Tablets Market, by Distribution Channel
9.1. Introduction
9.2. Hospital Pharmacy
9.3. Online Pharmacy
9.4. Retail Pharmacy
10. Savolitinib Tablets Market, by Dosage Strength
10.1. Introduction
10.2. 100 Mg
10.3. 200 Mg
11. Savolitinib Tablets Market, by Line Of Therapy
11.1. Introduction
11.2. First Line
11.3. Second Line
11.4. Third Line And Beyond
12. Savolitinib Tablets Market, by Patient Type
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Americas Savolitinib Tablets Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Savolitinib Tablets Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Savolitinib Tablets Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AstraZeneca Pharmaceutical (China) Investment Co., Ltd.
16.3.2. Hutchison China MediTech Limited
17. ResearchAI18. ResearchStatistics19. ResearchContacts20. ResearchArticles21. Appendix
List of Figures
FIGURE 1. SAVOLITINIB TABLETS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2030 (%)
FIGURE 6. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 8. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2030 (%)
FIGURE 10. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 12. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2030 (%)
FIGURE 14. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. SAVOLITINIB TABLETS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. SAVOLITINIB TABLETS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. SAVOLITINIB TABLETS MARKET: RESEARCHAI
FIGURE 26. SAVOLITINIB TABLETS MARKET: RESEARCHSTATISTICS
FIGURE 27. SAVOLITINIB TABLETS MARKET: RESEARCHCONTACTS
FIGURE 28. SAVOLITINIB TABLETS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. SAVOLITINIB TABLETS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY GASTRIC CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY C-MET EXON 14 SKIPPING MUTATION POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY C-MET EXON 14 SKIPPING MUTATION POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY EGFR MUTATION POSITIVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY EGFR MUTATION POSITIVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY 100 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY 100 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY 200 MG, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY 200 MG, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY FIRST LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY SECOND LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY THIRD LINE AND BEYOND, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL SAVOLITINIB TABLETS MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 69. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES SAVOLITINIB TABLETS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 79. CANADA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 80. CANADA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 81. CANADA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 82. CANADA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 83. CANADA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. CANADA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. CANADA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 86. CANADA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 87. CANADA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 88. CANADA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 89. CANADA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 90. CANADA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 91. MEXICO SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 92. MEXICO SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 93. MEXICO SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 94. MEXICO SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 95. MEXICO SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 96. MEXICO SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 97. MEXICO SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 98. MEXICO SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 99. MEXICO SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 100. MEXICO SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 101. MEXICO SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 102. MEXICO SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 103. BRAZIL SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 104. BRAZIL SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 105. BRAZIL SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 106. BRAZIL SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 107. BRAZIL SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 108. BRAZIL SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 109. BRAZIL SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 110. BRAZIL SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 111. BRAZIL SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 112. BRAZIL SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 113. BRAZIL SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 114. BRAZIL SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 115. ARGENTINA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 116. ARGENTINA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 117. ARGENTINA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 118. ARGENTINA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 119. ARGENTINA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 120. ARGENTINA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 121. ARGENTINA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 122. ARGENTINA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 123. ARGENTINA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 124. ARGENTINA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 125. ARGENTINA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 126. ARGENTINA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 134. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 135. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 136. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 137. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 138. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 139. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 140. EUROPE, MIDDLE EAST & AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 141. UNITED KINGDOM SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 142. UNITED KINGDOM SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 143. UNITED KINGDOM SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 144. UNITED KINGDOM SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 145. UNITED KINGDOM SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. UNITED KINGDOM SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. UNITED KINGDOM SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 148. UNITED KINGDOM SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 150. UNITED KINGDOM SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 151. UNITED KINGDOM SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 152. UNITED KINGDOM SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 153. GERMANY SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 154. GERMANY SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 155. GERMANY SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 156. GERMANY SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 157. GERMANY SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 158. GERMANY SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 159. GERMANY SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 160. GERMANY SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 161. GERMANY SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 162. GERMANY SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 163. GERMANY SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 164. GERMANY SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 165. FRANCE SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 166. FRANCE SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 167. FRANCE SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 168. FRANCE SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 169. FRANCE SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 170. FRANCE SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 171. FRANCE SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 172. FRANCE SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 173. FRANCE SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 174. FRANCE SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 175. FRANCE SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 176. FRANCE SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 177. RUSSIA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 178. RUSSIA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 179. RUSSIA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 180. RUSSIA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 181. RUSSIA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 182. RUSSIA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 183. RUSSIA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 184. RUSSIA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 185. RUSSIA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 186. RUSSIA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 187. RUSSIA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 188. RUSSIA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 189. ITALY SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 190. ITALY SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 191. ITALY SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 192. ITALY SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 193. ITALY SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 194. ITALY SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 195. ITALY SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 196. ITALY SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 197. ITALY SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 198. ITALY SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 199. ITALY SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 200. ITALY SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 201. SPAIN SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 202. SPAIN SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 203. SPAIN SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 204. SPAIN SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 205. SPAIN SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. SPAIN SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. SPAIN SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 208. SPAIN SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 209. SPAIN SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 210. SPAIN SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 211. SPAIN SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 212. SPAIN SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 213. UNITED ARAB EMIRATES SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED ARAB EMIRATES SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED ARAB EMIRATES SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 216. UNITED ARAB EMIRATES SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 217. UNITED ARAB EMIRATES SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 218. UNITED ARAB EMIRATES SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 219. UNITED ARAB EMIRATES SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 220. UNITED ARAB EMIRATES SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 221. UNITED ARAB EMIRATES SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 222. UNITED ARAB EMIRATES SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 223. UNITED ARAB EMIRATES SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 225. SAUDI ARABIA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 226. SAUDI ARABIA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 227. SAUDI ARABIA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 228. SAUDI ARABIA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 229. SAUDI ARABIA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 230. SAUDI ARABIA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 231. SAUDI ARABIA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 232. SAUDI ARABIA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 233. SAUDI ARABIA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 234. SAUDI ARABIA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 235. SAUDI ARABIA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 236. SAUDI ARABIA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 237. SOUTH AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 238. SOUTH AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 239. SOUTH AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 240. SOUTH AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 241. SOUTH AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 242. SOUTH AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 243. SOUTH AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 244. SOUTH AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 245. SOUTH AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 246. SOUTH AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 247. SOUTH AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 248. SOUTH AFRICA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 249. DENMARK SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 250. DENMARK SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 251. DENMARK SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 252. DENMARK SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 253. DENMARK SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 254. DENMARK SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 255. DENMARK SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 256. DENMARK SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 257. DENMARK SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 258. DENMARK SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 259. DENMARK SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 260. DENMARK SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 261. NETHERLANDS SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 262. NETHERLANDS SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 263. NETHERLANDS SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 264. NETHERLANDS SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 265. NETHERLANDS SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. NETHERLANDS SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. NETHERLANDS SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 268. NETHERLANDS SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 269. NETHERLANDS SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 270. NETHERLANDS SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 271. NETHERLANDS SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 272. NETHERLANDS SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 273. QATAR SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 274. QATAR SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 275. QATAR SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 276. QATAR SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 277. QATAR SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 278. QATAR SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 279. QATAR SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 280. QATAR SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 281. QATAR SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 282. QATAR SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 283. QATAR SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 284. QATAR SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 285. FINLAND SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 286. FINLAND SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 287. FINLAND SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 288. FINLAND SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 289. FINLAND SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 290. FINLAND SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 291. FINLAND SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 292. FINLAND SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 293. FINLAND SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 294. FINLAND SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 295. FINLAND SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 296. FINLAND SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 297. SWEDEN SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 298. SWEDEN SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 299. SWEDEN SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 300. SWEDEN SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 301. SWEDEN SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 302. SWEDEN SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 303. SWEDEN SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 304. SWEDEN SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 305. SWEDEN SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 306. SWEDEN SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 307. SWEDEN SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 308. SWEDEN SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 309. NIGERIA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 310. NIGERIA SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 311. NIGERIA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 312. NIGERIA SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 313. NIGERIA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 314. NIGERIA SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 315. NIGERIA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 316. NIGERIA SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 317. NIGERIA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 318. NIGERIA SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 319. NIGERIA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2018-2024 (USD MILLION)
TABLE 320. NIGERIA SAVOLITINIB TABLETS MARKET SIZE, BY PATIENT TYPE, 2025-2030 (USD MILLION)
TABLE 321. EGYPT SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
TABLE 322. EGYPT SAVOLITINIB TABLETS MARKET SIZE, BY INDICATION, 2025-2030 (USD MILLION)
TABLE 323. EGYPT SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2024 (USD MILLION)
TABLE 324. EGYPT SAVOLITINIB TABLETS MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2025-2030 (USD MILLION)
TABLE 325. EGYPT SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 326. EGYPT SAVOLITINIB TABLETS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 327. EGYPT SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2024 (USD MILLION)
TABLE 328. EGYPT SAVOLITINIB TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2025-2030 (USD MILLION)
TABLE 329. EGYPT SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 330. EGYPT SAVOLITINIB TABLETS MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 331. EGYPT SAVOLITINIB TABLETS

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Savolitinib Tablets Market report include:
  • AstraZeneca Pharmaceutical (China) Investment Co., Ltd.
  • Hutchison China MediTech Limited

Related Topics

Related Reports

Osimertinib Mesylate Tablets Market - Global Forecast 2025-2030 - Product Image

Osimertinib Mesylate Tablets Market - Global Forecast 2025-2030

  • Report
  • 197 Pages
  • Global
From
Afatinib Tablets Market - Global Forecast 2025-2030 - Product Image

Afatinib Tablets Market - Global Forecast 2025-2030

  • Report
  • 190 Pages
  • Global
From
Nimesulide Dispersible Tablet Global Market Report 2025 - Product Image

Nimesulide Dispersible Tablet Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Isosorbide Mononitrate Tablet Global Market Report 2025 - Product Image

Isosorbide Mononitrate Tablet Global Market Report 2025

  • Report
  • 175 Pages
  • Global
From
Imipramine Hydrochloride Tablet Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application - Product Image

Imipramine Hydrochloride Tablet Market Insights 2025, Analysis and Forecast to 2030, by Market Participants, Regions, Technology, Application

  • Report
  • 74 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.